A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

• المؤلفون الرئيسيون: Chen, Yunxin, Gopalakrishnan, Sathish Kumar, Ooi, Melissa, Sultana, Rehena, Lim, Li Hui, Grigoropoulos, Nicholas, Ong, Shin Yeu, Xu, Mingge, Chng, Wee Joo, Goh, Yeow Tee, Nagarajan, Chandramouli
• مؤلفون آخرون: MEDICINE
• التنسيق: Letter
• اللغة: English
• منشور في: SPRINGERNATURE 2021
• الموضوعات: Science & Technology; Life Sciences & Biomedicine; Oncology; Hematology; MULTIPLE-MYELOMA; LENALIDOMIDE
• الوصول للمادة أونلاين: https://scholarbank.nus.edu.sg/handle/10635/207736
• المؤسسة: National University of Singapore

10.1038/s41408-021-00544-x